EMA recommends approval of new somatostatin analogue pasireotide (Signifor) for Cushing’s disease (NeLM News Service, 20 January 2012)
The European Medicines Agency has made a positive recommendation to the European Commission for EU approval for Novartis' Signifor (pasireotide) in the treatment of Cushing's disease.
Full article